![A, Change in controlled attenuation parameter (CAP) after treatment... | Download Scientific Diagram A, Change in controlled attenuation parameter (CAP) after treatment... | Download Scientific Diagram](https://www.researchgate.net/profile/Yoshimasa-Aso/publication/327419010/figure/fig1/AS:677387847077888@1538513256102/A-Change-in-controlled-attenuation-parameter-CAP-after-treatment-with-dapagliflozin-5.png)
A, Change in controlled attenuation parameter (CAP) after treatment... | Download Scientific Diagram
![Dapagliflozin Did Not Significantly Reduce Organ Failure or Death in High-Risk Hospitalized COVID-19 Patients | DAIC Dapagliflozin Did Not Significantly Reduce Organ Failure or Death in High-Risk Hospitalized COVID-19 Patients | DAIC](https://www.dicardiology.com/sites/default/files/styles/content_feed_large_new/public/COVID_Forxinga_dapagliflozin_ACC21.jpg?itok=fpdG0-s8)
Dapagliflozin Did Not Significantly Reduce Organ Failure or Death in High-Risk Hospitalized COVID-19 Patients | DAIC
![IJMS | Free Full-Text | Dapagliflozin Prevents NOX- and SGLT2-Dependent Oxidative Stress in Lens Cells Exposed to Fructose-Induced Diabetes Mellitus IJMS | Free Full-Text | Dapagliflozin Prevents NOX- and SGLT2-Dependent Oxidative Stress in Lens Cells Exposed to Fructose-Induced Diabetes Mellitus](https://www.mdpi.com/ijms/ijms-20-04357/article_deploy/html/images/ijms-20-04357-g005.png)
IJMS | Free Full-Text | Dapagliflozin Prevents NOX- and SGLT2-Dependent Oxidative Stress in Lens Cells Exposed to Fructose-Induced Diabetes Mellitus
![ACC 2021: AstraZeneca's Farxiga failed to help COVID-19 patients, but it's safe for them to use | Fierce Pharma ACC 2021: AstraZeneca's Farxiga failed to help COVID-19 patients, but it's safe for them to use | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1621102632/Farxiga.jpg/Farxiga.jpg?VersionId=tKwGafVnkpAGsElslL8L7lhELjuoe0XG)
ACC 2021: AstraZeneca's Farxiga failed to help COVID-19 patients, but it's safe for them to use | Fierce Pharma
![AstraZeneca's diabetes drug Farxiga nabs coveted kidney disease nod, way ahead of rival Jardiance | Fierce Pharma AstraZeneca's diabetes drug Farxiga nabs coveted kidney disease nod, way ahead of rival Jardiance | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1619989374/Farxiga%2010mg.jpg?VersionId=dHWdb1WN.E.nqpjVWVnOqyBuZk7JIEKD)